Grants for Special district governments - Food and Nutrition

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize care of persons with Type 2 diabetes from populations with health/health care disparities concordant with evidence-based guidelines. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations. Proposed projects would be expected to develop and/or test patient-centered strategies, which in addition to optimal glycemic control, would aim at completing other recommended guidelines (e.g., annual eye/foot and urine albumin exam, optimal blood pressure control, intake of ACEIs or ARBs/statin/aspirin and influenza/pneumonia vaccines).

This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish a Research Resource Center (RRC) for the NIDDK Nutrition Obesity Research Centers (NORC) Program. The NORC Program consists of eleven Centers across the nation that support and enhance the national research effort in nutrition and obesity through cutting-edge basic, clinical, translational, and health disparities research in nutrition science and obesity. In collaboration with the existing NORC program, the RRC will (1) provide administrative support for the entire NORC Program, (2) establish and curate a NORC Program website and centralized repository of research resources , (3) implement a multipronged approach to support and grow the early-to-midcareer research workforce, including individuals from diverse backgrounds, with a goal of maximizing national outreach and impact, (4) administer and manage a NORC Opportunity Program to address gaps and promote collaboration, and (5) manage a Pilot and Feasibility Program.This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.Research Objectives Utilizing the ACTC, the goal of this FOA is to invite research grant applications that provide clinical testing (Phases Ib-III) of promising pharmacological and/or non-pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD or other aging-related dementias across the spectrum from pre-symptomatic to more severe stages of disease. Working with the ACTC is a cooperative venture between the applicant, the NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. Potential applicants are strongly encouraged to contact NIA Scientific/Research Contacts (see Agency Contacts, Section VII) and the ACTC study team in order to discuss the feasibility of conducting the proposed trial through the ACTC infrastructure before considering an application. The ACTC infrastructure is welcoming of the following: Academic and industry applicants Pharmacological and non-pharmacological interventions Applications are encouraged that propose the following: Testing candidate therapeutic compounds against novel therapeutic targets Testing repurposed drugs derived from data-driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032) Logistical guidance: Potential applicants undergo initial vetting of proposed study by the ACTC protocol evaluation committee and final review by the steering committee. Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found at actcinfo.org. Applications should anticipate using a centralized IRB. Applicants should be aware of the data and resource sharing requirements. The use of common contract language is strongly encouraged. Note, the ACTC infrastructure is not appropriate for: Single site clinical trials Routine Phase Ia first-in-human Clinical trials funded from this FOA will be implemented through the ACTC. The clinical trials approved for funding will develop their final protocols in conjunction with the ACTC. All ACTC sites will have the option to request participation and will be selected based on their capabilities specific to the individual protocols. Investigators are strongly encouraged to collect blood and other biosamples for future genomic and other 'omic' analyses aimed at interrogating treatment responsiveness and examining predictors of decline and progression. See Section VIII. Other Information for award authorities and regulations.

This funding opportunity provides significant financial support to U.S. higher education institutions and research organizations with established HIV/AIDS research programs, enabling them to enhance their research infrastructure and foster interdisciplinary collaboration in the fight against HIV/AIDS.

This funding opportunity provides financial support to research institutions for developing and sharing essential resources to advance the study of Polycystic Kidney Disease, fostering collaboration and innovation in the field.

This funding opportunity provides financial support to public and nonprofit organizations to deliver comprehensive primary health care services in underserved communities across the United States.

This funding opportunity provides financial support to organizations implementing strategies to prevent diabetes and improve health equity for populations at risk, focusing on statewide, local, or multisectoral approaches.

The Silvio O. Conte Digestive Diseases Research Core Centers grant, provided by the NIDDK, supports collaborative research on digestive and liver diseases by offering shared resources to enhance productivity and foster new ideas, centered around a theme within the NIDDK's mission.

This funding opportunity supports research projects aimed at reducing stigma related to HIV/AIDS in low- and middle-income countries, with a focus on improving health outcomes for affected populations.

Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Conditions within the Missions of NIDDK and NHLBI (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.

This funding opportunity supports research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underserved communities, while also addressing the reduction of ineffective practices.

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

This funding opportunity supports researchers in developing innovative tools that can speed up drug development and improve regulatory processes, ultimately enhancing public health by facilitating faster access to effective treatments.

This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

The Rose Foundation is pleased to present this grant opportunity for water quality related projects in the Central Coast Regional Water Quality Control Board’s jurisdiction. Donor Name: Rose Foundation for Communities and the Environment State: California County: Kern County (CA), Monterey County (CA), San Benito County (CA), San Luis Obispo County (CA), San Mateo County (CA), Santa Barbara County (CA), Santa Clara County (CA), Santa Cruz County (CA), Ventura County (CA) Type of Grant: Grant Deadline: 06/28/2024 Size of the Grant: $100,000 to $500,000 Grant Duration: Grant Duration Not Mentioned Details: The Central Coast Community-Based Water Quality Grants Program supports projects that water quality related projects in the Central Coast Regional Water Quality Control Board’s jurisdiction, with an emphasis on projects that advance environmental justice and/or provide water quality benefits to underrepresented communities. The Rose Foundation is partnering with the Bay Foundation of Morro Bay in presenting this grant opportunity, and there will be a publicly available ranking and selection criteria utilized in the selection process.  Preferred topic areas include:  The human right to water  Environmental justice and local environmental justice capacity  Water quality impacts of climate change  Drought related water supply resiliency projects  Climate adaptation and mitigation projects  Sustainable drinking water or wastewater treatment solutions  Sustainable groundwater management strategies  Providing benefits to Underrepresented Communities Additional topic areas include, but are not limited to the following:  Projects that provide water quality benefits to marine habitats and associated beneficial uses in San Luis Obispo County. Implementation of activities that will reduce pollutant loading and make measurable progress toward meeting water quality objectives established in the Central Coast Basin Plan.  Water quality improvement or restoration projects that preserve and restore watershed functions and support healthy ecosystems, especially in impaired waterbodies identified on the 303(d) List and associated Total Maximum Daily Loads (TMDLs). On-farm Best Management Practice (BMP) implementation projects that demonstrate reductions in salt and nitrate loading, especially projects that assist limited resource farmers.  Projects that prevent or address Harmful Algal Blooms (HABs) Funding Information Large Grant Track is for funding requests of up to $200,000, and most grants will be in the $100,000-200,000 range. Small Grant Track is for funding requests of up to $50K, and most grant awards will be in the $20-$50K range. Eligibility Criteria Applicants must be one of the following: 501(c)(3) Nonprofit organizations Federally recognized Indian tribes or State Indian tribes listed on the Native American Heritage Commission’s Tribal Consultation List Public agencies (e.g., counties, cities, districts), including agencies having jurisdiction over water resources management, drinking water, or treatment and disposal/reuse of municipal wastewater or other wastes Projects must be conducted within the jurisdiction of the Central Coast Water Board, identified as Region 3. (Region 3 includes Southern Santa Clara (Morgan Hill and south), Santa Cruz, San Benito, Monterey, San Luis Obispo, and Santa Barbara Counties, and small portions of Ventura, Kern, and San Mateo Counties).  For more information, visit Rose Foundation for Communities.

This funding opportunity supports innovative research that investigates how aging affects individuals living with HIV, focusing on improving their health outcomes and addressing related challenges.

This funding opportunity supports innovative, interdisciplinary research projects that aim to fill critical knowledge gaps and advance scientific understanding in areas related to kidney, diabetes, and digestive diseases.

This funding opportunity supports students enrolled in dual-degree medical and research training programs, helping them develop into independent physician-scientists through mentored research and clinical training.